Developer docs
API playgroundTry for free, no card

Search company profiles

Baudax Bio

Full company profile

uuid0005t93

Namestring
Baudax Bio
Legal namestring
Baudax Bio, Inc.
Websiteurl
baudaxbio.com
Company typeenum
Public
Founded yearint
2015
Short descriptiontext

Baudax Bio is a public specialty pharmaceutical company commercializing ANJESO, a hospital-use NSAID, while developing the acquired TI-168 TCR-Treg cell therapy platform for Hemophilia A patients with factor VIII inhibitors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMalvern, United States
HQ citystring
Malvern
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
specialty pharmaceuticals, hospital acute care, NSAID pain management, cell therapy pipeline, clinical-stage biopharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
Revenue model2 records
1Product Sales (ANJESO)
TypeHardware Sales
Description

Revenue generated from the commercialization of ANJESO, a marketed NSAID product targeted at hospital use.

globenewswire.com
2Pipeline Development
TypeProfessional Services
Description

Ongoing development of clinical-stage assets funded through capital raises, with proceeds allocated to working capital, pipeline advancement, and general corporate purposes.

biospace.com
Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1ANJESO
Description

Marketed NSAID product for hospital use

biospace.com
Core offering1 text field

Baudax Bio is a specialty pharmaceutical company that develops and commercializes innovative products for acute care settings. Its commercially available product is ANJESO, an NSAID used for post-operative pain management in hospitals. The company is also developing a clinical-stage pipeline, led by the TI-168 autologous FVIII TCR-Treg cell therapy acquired from TeraImmune for treating Hemophilia A patients with clotting factor VIII inhibitors.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1ANJESO
CategorySpecialty Pharmaceutical Product
Description

A marketed NSAID (Non-Steroidal Anti-Inflammatory Drug) designed for hospital use, targeting post-operative pain management in acute care settings for surgical inpatients.

2TI-168
CategoryCell Therapy / Clinical-Stage Biopharmaceutical
Description

A clinical-stage autologous FVIII TCR-Treg cell therapy asset acquired from TeraImmune, designed to treat Hemophilia A patients who have developed clotting factor VIII inhibitors.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1AES Clean Technology Inc.
Strategic tierMinorTypeOthersAnnounced on2026-04-01
Description

AES Clean Technology Inc. introduced the Cleanlock module, a modular cleanroom airlock system designed to support pharmaceutical manufacturing quality control. Referenced in a market analysis covering Baudax Bio's therapeutic area. No direct commercial relationship with Baudax Bio is described.

2TeraImmune, Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-01
Description

Baudax Bio completed the acquisition of TeraImmune, Inc. in June 2023, bringing the TI-168 autologous FVIII TCR-Treg cell therapy asset into Baudax's pipeline. The acquisition is intended to capitalize on T-cell Receptor (TCR)-Treg cell therapy platform for Hemophilia A patients with inhibitors. This acquisition represents the company's entry into the cell therapy space for rare bleeding disorders.

Peers10 records
1Quell Therapeutics
TypeEmerging player
2Sonoma Biotherapeutics
TypeDirect peer
Description

Clinical-stage biotech developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. Directly comparable to Baudax Bio's TCR-Treg platform as a peer in the emerging Treg cell therapy space with proprietary engineered Treg technology.

3Pacira BioSciences
TypeDirect peer
Description

Specialty hospital-focused pharmaceutical company marketing EXPAREL, a long-acting postsurgical pain product. Directly comparable to Baudax Bio's ANJESO business in targeting hospital-based post-operative pain management through differentiated, hospital-channel therapeutics.

4Sangamo Therapeutics
TypeDirect peer
Description

Clinical-stage gene and cell therapy company with a Hemophilia A program (and other rare-disease assets). Directly comparable on the TI-168 side as a small-cap developer of novel therapies for Hemophilia A patients with inhibitors, using advanced biologic modalities.

5Pfizer
TypeBroad incumbent
Description

Large pharmaceutical company with multiple Hemophilia A and broader hematology assets through its rare-disease portfolio. Comparable as a dominant incumbent in the Hemophilia A treatment market relevant to TI-168.

6Heron Therapeutics
TypeDirect peer
Description

Specialty pharma developing HTX-011 and other hospital/postoperative pain therapeutics. Closely comparable to Baudax Bio as a small-cap, hospital-channel pain management company with a marketed product and pipeline challenges typical of the segment.

7Tarsus Pharmaceuticals
TypeOthers
Description

Small-cap specialty pharmaceutical company commercializing a single differentiated therapy in a focused therapeutic area. Comparable to Baudax Bio as a publicly traded, narrowly focused specialty pharma with a single marketed asset and limited pipeline diversification.

8GentiBio
TypeDirect peer
Description

Emerging engineered Treg cell therapy company developing autologous and allogeneic Tregs for autoimmune and inflammatory indications. Directly comparable to Baudax Bio on the TCR-Treg platform side, given both companies are pursuing Treg-based cell therapies for immune-mediated disease.

9Mallinckrodt
TypeBroad incumbent
Description

Specialty pharmaceutical company with a hospital-focused portfolio including analgesics and other acute-care products. Comparable to Baudax Bio's hospital-channel commercial positioning and acute-care specialty pharma orientation.

10BioMarin Pharmaceutical
TypeBroad incumbent
Description

Established rare-disease biotech with a marketed/recently approved Hemophilia A gene therapy (ROCTAVIAN) and broader hematology franchise. Comparable as a major Hemophilia A therapeutics player addressing the same patient population that TI-168 targets.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Baudax Bio

Specialty Pharmaceuticalsbaudaxbio.com

Baudax Bio is a public specialty pharmaceutical company commercializing ANJESO, a hospital-use NSAID, while developing the acquired TI-168 TCR-Treg cell therapy platform for Hemophilia A patients with factor VIII inhibitors.

Baudax Bio firmographics

Firmographics
Name
Baudax Bio
Legal name
Baudax Bio, Inc.
Website
https://baudaxbio.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Baudax Bio is a public specialty pharmaceutical company commercializing ANJESO, a hospital-use NSAID, while developing the acquired TI-168 TCR-Treg cell therapy platform for Hemophilia A patients with factor VIII inhibitors.
Ownership category
akta.pro rank

Where Baudax Bio is headquartered

Location

Headquarters

HQ city
Malvern
HQ country
United States
HQ region
North America

Markets served

Baudax Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Product Sales (ANJESO): Revenue generated from the commercialization of ANJESO, a marketed NSAID product targeted at hospital use.
  2. Pipeline Development: Ongoing development of clinical-stage assets funded through capital raises, with proceeds allocated to working capital, pipeline advancement, and general corporate purposes.

Baudax Bio product offering

Product offering

Core offering

Baudax Bio is a specialty pharmaceutical company that develops and commercializes innovative products for acute care settings. Its commercially available product is ANJESO, an NSAID used for post-operative pain management in hospitals. The company is also developing a clinical-stage pipeline, led by the TI-168 autologous FVIII TCR-Treg cell therapy acquired from TeraImmune for treating Hemophilia A patients with clotting factor VIII inhibitors.

Differentiator

Problem solved

Functional benefit

Brands

  • ANJESO: Marketed NSAID product for hospital use

Products and services

  • ANJESO A marketed NSAID (Non-Steroidal Anti-Inflammatory Drug) designed for hospital use, targeting post-operative pain management in acute care settings for surgical inpatients.
  • TI-168 A clinical-stage autologous FVIII TCR-Treg cell therapy asset acquired from TeraImmune, designed to treat Hemophilia A patients who have developed clotting factor VIII inhibitors.

Companies that use Baudax Bio

Customer profile

Segments1 record

Ideal customer profiles1 record

Baudax Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Baudax Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • AES Clean Technology Inc.minorOthers · 1 April 2026AES Clean Technology Inc. introduced the Cleanlock module, a modular cleanroom airlock system designed to support pharmaceutical manufacturing quality control. Referenced in a market analysis covering Baudax Bio's therapeutic area. No direct commercial relationship with Baudax Bio is described.
  • TeraImmune, Inc.coreStrategic or Co-development Partner · 1 June 2023Baudax Bio completed the acquisition of TeraImmune, Inc. in June 2023, bringing the TI-168 autologous FVIII TCR-Treg cell therapy asset into Baudax's pipeline. The acquisition is intended to capitalize on T-cell Receptor (TCR)-Treg cell therapy platform for Hemophilia A patients with inhibitors. This acquisition represents the company's entry into the cell therapy space for rare bleeding disorders.

Scale indicators7 records

Baudax Bio competitors and assessment

Company assessment

Emerging players

Direct peers

  • Sonoma Biotherapeutics: Clinical-stage biotech developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. Directly comparable to Baudax Bio's TCR-Treg platform as a peer in the emerging Treg cell therapy space with proprietary engineered Treg technology.
  • Pacira BioSciences: Specialty hospital-focused pharmaceutical company marketing EXPAREL, a long-acting postsurgical pain product. Directly comparable to Baudax Bio's ANJESO business in targeting hospital-based post-operative pain management through differentiated, hospital-channel therapeutics.
  • Sangamo Therapeutics: Clinical-stage gene and cell therapy company with a Hemophilia A program (and other rare-disease assets). Directly comparable on the TI-168 side as a small-cap developer of novel therapies for Hemophilia A patients with inhibitors, using advanced biologic modalities.
  • Heron Therapeutics: Specialty pharma developing HTX-011 and other hospital/postoperative pain therapeutics. Closely comparable to Baudax Bio as a small-cap, hospital-channel pain management company with a marketed product and pipeline challenges typical of the segment.
  • GentiBio: Emerging engineered Treg cell therapy company developing autologous and allogeneic Tregs for autoimmune and inflammatory indications. Directly comparable to Baudax Bio on the TCR-Treg platform side, given both companies are pursuing Treg-based cell therapies for immune-mediated disease.

Broad incumbents

  • Pfizer: Large pharmaceutical company with multiple Hemophilia A and broader hematology assets through its rare-disease portfolio. Comparable as a dominant incumbent in the Hemophilia A treatment market relevant to TI-168.
  • Mallinckrodt: Specialty pharmaceutical company with a hospital-focused portfolio including analgesics and other acute-care products. Comparable to Baudax Bio's hospital-channel commercial positioning and acute-care specialty pharma orientation.
  • BioMarin Pharmaceutical: Established rare-disease biotech with a marketed/recently approved Hemophilia A gene therapy (ROCTAVIAN) and broader hematology franchise. Comparable as a major Hemophilia A therapeutics player addressing the same patient population that TI-168 targets.

Others

  • Tarsus Pharmaceuticals: Small-cap specialty pharmaceutical company commercializing a single differentiated therapy in a focused therapeutic area. Comparable to Baudax Bio as a publicly traded, narrowly focused specialty pharma with a single marketed asset and limited pipeline diversification.

Market position

Customer concentration

Baudax Bio social profiles

Digital presence

Baudax Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Baudax Bio leadership team

Management profile

Number of profiles

Profiles3 records

Baudax Bio subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Baudax Bio funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Baudax Bio M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baudax Bio

What does Baudax Bio do?

Baudax Bio is a specialty pharmaceutical company that develops and commercializes innovative products for acute care settings. Its commercially available product is ANJESO, an NSAID used for post-operative pain management in hospitals. The company is also developing a clinical-stage pipeline, led by the TI-168 autologous FVIII TCR-Treg cell therapy acquired from TeraImmune for treating Hemophilia A patients with clotting factor VIII inhibitors.

Is Baudax Bio a public or private company?

Baudax Bio is a public company. It is classified as public and is currently operating.

When was Baudax Bio founded?

Baudax Bio was founded in 2015. It employs 51 to 100 people.

Where is Baudax Bio based?

Baudax Bio is headquartered in Malvern, United States, in the North America region.

How does Baudax Bio make money?

Two revenue lines are on record. Product Sales (ANJESO) is the primary driver. The others are pipeline Development.

Who are Baudax Bio's main competitors?

Quell Therapeutics is listed as an emerging player. Direct peers are Sonoma Biotherapeutics, Pacira BioSciences, Sangamo Therapeutics, Heron Therapeutics and GentiBio. Broad incumbents are Pfizer, Mallinckrodt and BioMarin Pharmaceutical. Tarsus Pharmaceuticals is listed as an others.

Does Baudax Bio have an API?

No public API is recorded for Baudax Bio.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comEmerging Growth Patterns Driving Expansion in the Bleeding Disorders Treatment MarketThe bleeding disorders treatment market is projected to reach $27.99 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.6%, driven by advancements in gene and biologic therapies and increased investment in rare disease research. In June 2023, US-based biopharmaceutical firm Baudax Bio, Inc. completed the acquisition of TeraImmune, Inc. to capitalize on its T-cell Receptor (TCR)-Treg cell therapy platform for Hemophilia A patients with inhibitors. Additionally, in April 2024, AES Clean Technology Inc. introduced the Cleanlock module, a modular cleanroom airlock system designed to support pharmaceutical manufacturing quality control.openPR.comEmerging Growth Patterns Driving Rapid Expansion in the Acquired Hemophilia Treatment MarketThe acquired hemophilia treatment market is projected to reach $15.91 billion by 2030, growing at a compound annual growth rate of 4.4%, driven by gene therapy breakthroughs and increased research investment. In June 2023, US-based Baudax Bio acquired TeraImmune Inc., bringing the TI-168 autologous FVIII TCR-Treg cell therapy asset into Baudax's pipeline for treating Hemophilia A patients with clotting factor VIII inhibitors. The market report profiles leading pharmaceutical companies including Roche, Novo Nordisk, Takeda, and Pfizer, while detailing treatment segmentation across bleeding control and inhibitor eradication therapies.GlobeNewswireDelisting of Securities of Sono Group N.V.; Baudax Bio, Inc.; Comera Life Sciences Holdings, Inc.; Missfresh Limited; Rose Hill Acquisition Corporation; Axcella Health; Zivo Bioscience, Inc.; Sonic FoNasdaq announced delisting of common shares for Sono Group N.V. and other companies, including Baudax Bio, Comera Life Sciences, Missfresh, Rose Hill, Axcella Health, Zivo Bioscience, Sonic Foundry, Mobiquity, Cuentas, micromobility.com, Harbor Custom Development, Nogin, Disruptive Acquisition Corp I, and Ebix. Each company's securities had been suspended since late 2023 or early 2024.PR NewswireThinking about buying stock in Arch Capital Group, Oncolytics Biotech, Baudax Bio, Femasys, or Traction Uranium?InvestorsObserver issued PriceWatch Alerts for Arch Capital Group, Oncolytics Biotech, Baudax Bio, Femasys, and Traction Uranity on September 27, 2023. The alerts utilize a proprietary scoring system that evaluates short-term technical, long-term technical, and fundamental factors to determine investment suitability. InvestorsObserver provides these analytical tools to both institutional investors on Wall Street and self-directed retail investors.GlobeNewswireBaudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesBaudax Bio announced a $1.9 million registered direct offering of its common stock and concurrent private placement of warrants, priced at $0.56 per share under Nasdaq rules. The company intends to utilize the net proceeds for pipeline development activities and general corporate purposes. Closing of the offerings is expected around August 21, 2023.citybizBaudax Bio Announces $1.9 Million Registered Direct OfferingBaudax Bio, Inc. announced a registered direct offering and concurrent private placement to raise approximately $1.9 million by issuing 2,006,544 shares of common stock and associated warrants at $0.56 per share. The company intends to use the net proceeds for pipeline development activities and general corporate purposes, with closing expected around August 21, 2023.FinSMEsBaudax Bio Acquires TeraImmuneBaudax Bio acquired TeraImmune, a Germantown, MD-based biotechnology company, for an undisclosed amount. TeraImmune develops Treg-based cell therapies for autoimmune diseases, and its CEO will lead the combined entity. Yong Chan Kim will join Baudax's board.BenzingaWhat's Happening With Baudax Bio Shares TodayBaudax Bio Inc (NASDAQ:BXRX) shares surged after the company announced the acquisition of privately held biotechnology company TeraImmune, which is focused on developing novel Treg-based cell therapies for autoimmune diseases. The merger adds TeraImmune's TI-168 asset to Baudax's portfolio — an autologous FVIII TCR-Treg cell therapy candidate for Hemophilia A patients that has already received FDA IND clearance — with a Phase 1/2a clinical trial planned using a modest initial budget. The company also reported additional positive results from its Phase 2 trial of BX1000 for neuromuscular blockade in patients undergoing elective surgery.BenzingaBaudax Bio Touts Additional Positive Data From Nerve Blocker In Surgery PatientsBaudax Bio Inc announced additional results from its Phase 2 trial of BX1000 for neuromuscular blockade in 80 adult patients undergoing elective surgery, showing that the highest dose of BX1000 compares favorably to the standard treatment rocuronium. The EMG analyses demonstrated comparable efficacy between BX1000 and rocuronium, with BX1000 showing tighter, more predictable margins for full recovery. The company's shares traded down 0.88% at $0.56 following the announcement.BenzingaWhy Baudax Bio (BXRX) Stock Is Soaring TodayBaudax Bio Inc announced positive top-line results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade in elective surgery patients, with the drug meeting the primary endpoint of readiness for intubation at all dose levels and no severe adverse events observed. The company plans to submit a New Drug Application for BX1000 by approximately year-end 2025. Following the announcement, BXRX shares surged approximately 32% to $2.48.